Recursion Pharmaceuticals, Inc. (RXRX) Tops Q1 EPS by 1c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $12.13 million versus the consensus estimate of $12.97 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Cloudflare Inc. (NET) PT Raised to $330 at Citizens on Infrastructure Subsector Strength
• Goldman Sachs Reinstates Genesis Minerals Ltd (GMD:AU) at Buy
• Domino's Pizza (DPZ) Misses Q2 EPS by 12c, Beats on Revenue